A 10-Year Survey of Mycobacterium tuberculosis Isolates in Pavia and Their Drug Resistance: a Comparison with Other Italian Reports

References

• World Health Report, 1999: making a difference. Geneva: World Health Organization 1999.
   Google Scholar
• Raviglione MC, Dye C, Schmidt S, Kochi A. Assessment of worldwide tuberculosis control. Lancet 1997; 350: 624–9.
   PubMed Web of Science ®Google Scholar
• Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677–86.
   PubMed Web of Science ®Google Scholar
• Johnson JL, Ellner JJ. Adult tuberculosis overview: African versus Western perspectives. Curr Opin Pulm Med 2000; 6: 180–6.
   PubMedGoogle Scholar
• Bleed D, Dye C, Raviglione MC. Dynamics and control of the global tuberculosis epidemic. Curr Opin Pulm Med 2000; 6: 174–9.
   PubMedGoogle Scholar
• Pollard AJ, Dobson SR. Emerging infectious diseases in the 21” century. Curr Opin Infect Dis 2000; 13: 265–75.
   PubMed Web of Science ®Google Scholar
• Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665–71.
   PubMed Web of Science ®Google Scholar
• Franzetti F, Gori A, Iemoli E, et al. Outcome of mul-tidrug-resistant tuberculosis in human imunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 553–60.
   PubMed Web of Science ®Google Scholar
• Willcox PA. Drug-resistant tuberculosis. Curr Opin Pulm Med 2000; 6: 198–202.
   PubMedGoogle Scholar
• Riska PF, Jacobs WR Jr, Alland D. Molecular determi-nats of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4 (Suppl 1): S4–10.
   PubMedGoogle Scholar
• Musser JM. Antimicrobial agent resistance in mycobac-teria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496–514.
   PubMed Web of Science ®Google Scholar
• Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294–303.
   PubMed Web of Science ®Google Scholar
• Collins CH, Grange JM, Yates MD. Organization and practice in tuberculosis bacteriology. London: Butterworths, 1985.
   Google Scholar
• Canetti G, Froman S, Grasset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565–78.
   PubMed Web of Science ®Google Scholar
• Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programs. Bull World Health Organ 1969; 41: 21–43.
   PubMed Web of Science ®Google Scholar
• Heifets L, Sanchez T. New Agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2000; 38: 1498–501.
   PubMed Web of Science ®Google Scholar
• Maggi N, Pasqualucci CR, Ballotta R Sensi P. Rifampicin a new orally active rifamycine. Chemotherapy 1966; 11: 285–92.
   Google Scholar
• Dye C, Williams BC. Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci USA 2000; 97: 8180–5.
   PubMed Web of Science ®Google Scholar
• Pablos-Mendez A, Sterling TR, Frieden TR. The rela-tionship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223–8.
   PubMed Web of Science ®Google Scholar
• Turett GS, Telzak EE, Torian LV, et al. Improved out-comes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1238–44.
   PubMed Web of Science ®Google Scholar
• Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-45.
   Google Scholar
• Irish C, Herbert J, Bennett D, et al. Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. Br Med J 1999; 318: 497–8.
   PubMedGoogle Scholar
• Migliori GB, Vaccarino P, Ianni A, et al. Prevalence of drug resistance to antituberculosis drugs in immigrants and HIV positive cases in Italy. Eur Resp J 2000; 16 (Suppl 31): 147S.
   Google Scholar
• Gilad J, Borer A, Riesenberg K, Peled N, Schlaeffer F. Epidemiology and ethnic distribution of multidrug-resistant tuberculosis in southern Israel, 1992-1997: the impact of immigration. Chest 2000; 117: 738–43.
   PubMed Web of Science ®Google Scholar
• Codecasa LR, Porretta AD, Cori A, et al. Tuberculosis among immigrants from developing countries in the province of Milan, 1993-1996. Int J Tuberc Lung Dis 1999; 3: 589–95.
   PubMed Web of Science ®Google Scholar
• Petrini B, Hoffner S. Drug-resistant and multidrug-resis-tant tubercle bacilli. Int J Antimicrob Agents 1999; 13: 93–7.
   PubMed Web of Science ®Google Scholar
• Schluger NW. The impact of drug resistance on the global tuberculosis epidemic. Int J Tuberc Lung Dis 2000; 4: S71–5.
   PubMed Web of Science ®Google Scholar
• Girardi E, Antonucci G, Tronci M, Bordi E, Ippolito G. Drug resistance patterns among tuberculosis patients in Rome, 1990-1992. Scand J Infect Dis 1996; 28: 487–91.
   PubMed Web of Science ®Google Scholar
• Nutini S, Tortoli E, Corrado A. Multidrug-resistant tuberculosis in the Florence province from 1992 to 1995. Int J Tuberc Lung Dis 1998; 2: 484–9.
   PubMed Web of Science ®Google Scholar
• Salamina G, Sodano L, Mezzetti F, Moro ML. The threat of multidrug-resistant tuberculosis: results of 1 yr of sur-veillance in the Lombardy region of Italy. Monaldi Arch Chest Dis 1999; 54: 332–6.
   PubMedGoogle Scholar
• Ambrosetti M, Besozzi G, Codecasa LR, et al. The Italian AIPO study on tuberculosis treatment results, report 1995. National AIPO “Tuberculosis” Study Group. Monaldi Arch Chest Dis 1999; 54: 49–54.
   PubMedGoogle Scholar
• Ambrosetti M, Besozzi G, Farris B, et al. The Italian AIPO study on tuberculosis treatment results, report 1996. National AIPO “Tuberculosis” Study Group. Associazione Italiana Pneumologi Ospedalieri. Monaldi Arch Chest Dis 1999; 54: 237–41.
   PubMedGoogle Scholar
• Ambrosetti M, Besozzi G, Codecasa LR, et al. The Italian AIPO study on tuberculosis treatment results, report 1997. National AIPO “Tuberculosis” Study Group. Monaldi Arch Chest Dis 1999; 54: 407–12.
   PubMedGoogle Scholar
• Centis R, Ianni A, Migliori GB. Evaluation of tuberculo-sis treatment results in Italy, report 1998. Tuberculosis section of the National AIPO Study Group on Infectious Disease and the SMIRA Group. Monaldi Arch Chest Dis 2000; 55: 293–8.
   PubMedGoogle Scholar
• Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculo-sis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137–44.
   PubMed Web of Science ®Google Scholar
• Van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174–9.
   PubMed Web of Science ®Google Scholar
• Sandman L, Schluger NW, Davidow AL, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 1999; 159: 468–72.
   PubMed Web of Science ®Google Scholar
• Yuen LKW, Leslie D, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuber-culosis strains isolated in Australia. J Clin Microbiol 1999; 37: 3844–50.
   PubMed Web of Science ®Google Scholar
• Ridzon R, Whitney CG, Mckenna MT, et al. Risk fac-tors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881–4.
   PubMed Web of Science ®Google Scholar
• Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25: 1465–7.
   PubMed Web of Science ®Google Scholar
• Moro ML, Cori A, Errante I, et al. An outbreak of mul-tidrug-resistant tuberculosis involving HIV-infected patients of two hospital in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998; 12: 1095–102.
   Google Scholar